NCT05895929View on ClinicalTrials.gov

The Role of IL5 in Epithelial Cell Integrity

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 5, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Chronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis (Diagnosis)
Interventions
DRUG

Mepolizumab

In vitro exposure of human nasal epithelial cells to mepolizumab

Trial Locations (2)

21117

RECRUITING

Johns Hopkins Bayview Medical Center, Baltimore

21287

RECRUITING

Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT05895929 - The Role of IL5 in Epithelial Cell Integrity | Biotech Hunter | Biotech Hunter